Read the source
255 sources to explore, from clinical trials and reviews to animal research, preprints, and commentary. These forms of evidence answer different questions.
Read each original source for its methods and limitations. Summaries are a starting point; inclusion here does not establish safety or effectiveness. Repeated source links appear once, with their substance associations retained.
255 sources
No sources match these filters. Try a broader search or clear the filters.
Caudevilla-Gálligo et al. 2012 J Psychopharmacology. Survey of 2C-B users (n=98) documenting patterns of use, subjective effects, and market presence in Spain.
Páleníček et al. 2013 Psychopharmacology. Preclinical study characterizing 2C-B pharmacology, serotonin release, and EEG changes compared to other psychedelics.
2020 Annals of Emergency Medicine. Clinical case series examining 2C-B toxicity presentations and outcomes in analytically confirmed cases.
Jefferson et al. 2023 Neuropsychopharmacology study showing 5-MeO-DMT affects behavioral patterns and promotes dendritic spine growth in rodent brain tissue.
Overall 2025 Applied Psychology Research. Mixed-methods analysis examining 5-MeO-DMT's role in mental health and intergenerational healing processes.
Hayes 2025 Psychedelic Medicine. Review examining evidence for 5-MeO-DMT in depression treatment and its therapeutic potential.
Armstrong et al. 2023 Military Psychology study on psychedelic-assisted treatment for co-occurring alcohol misuse and PTSD in US Special Operations Forces Veterans.
Uthaug et al. 2019 Psychopharmacology naturalistic study. Single vapor inhalation of toad-derived 5-MeO-DMT related to lasting improvements in life satisfaction and mindfulness.
Kargbo 2024 ACS Medicinal Chemistry Letters. Review of 5-MeO-DMT and DMT therapeutic potential, covering pharmacology, clinical development, and mental health applications.
Barsuglia, Davis et al. 2018 Frontiers in Psychology. Showed 5-MeO-DMT produces mystical experiences comparable in intensity to high-dose psilocybin, with potential therapeutic implications.
Lancelotta, Davis 2020 J Psychoactive Drugs. Survey examining how preparation and integration practices affect 5-MeO-DMT outcomes and long-term benefits.
Lancelotta 2022 Human Psychopharmacology. Critical safety warning about lethal risks of combining 5-MeO-DMT with MAOIs, clarifying 5-MeO-DMT is not present in traditional ayahuasca.
Vengeliene et al. 2008 comprehensive review of alcohol's effects on mesolimbic dopamine, GABA, glutamate, serotonin, and opioid systems. Explains how chronic use recruits anti-reward/stress mechanisms driving compulsive drinking. Published in British Journal of Pharmacology.
Jesse et al. 2021 clinical review of alcohol withdrawal management including seizure risk, delirium tremens, and evidence-based pharmacotherapy with benzodiazepines and anticonvulsants. Published in Drugs.
Mukherjee 2022 review covering alcohol's multi-system neurotoxicity, epigenetic modifications, neuroinflammation, and gut-brain axis disruption. Covers FDA-approved treatments: naltrexone, acamprosate, and disulfiram. Published in Biomedicines.
2024 literature review on how repeated withdrawal episodes (kindling) cause cumulative brain damage. Optimized acute withdrawal management may prevent long-term cognitive decline and Wernicke-Korsakoff syndrome.
Bates et al. 2002 review of how alcohol-induced neurotoxicity causes measurable cognitive impairment affecting executive function, memory, and visuospatial abilities, with implications for treatment outcomes.
Reynolds et al. 2019 study demonstrating that ethanol withdrawal causes dose-dependent hippocampal neuron death via AMPA and mGluR5 glutamate receptors. AMPA antagonists attenuated toxicity, suggesting neuroprotective treatment targets.
2025 systematic analysis of ClinicalTrials.gov registrations for AUD treatments. Maps the landscape of GABAergic, glutamatergic, opioidergic, and serotonergic targets being pursued in active clinical trials.
Brands et al. 2008 naturalistic study — first to examine clinical impact of benzodiazepine co-dependence on opiate withdrawal. Co-dependent patients had more severe withdrawal and lower detoxification completion rates.
Sun et al. 2017 study of Medicare beneficiaries showing concurrent benzodiazepine use is associated with a 5-fold increase in opioid-related overdose risk during the first 90 days. Published in JAMA Network Open.
Votaw et al. 2019 systematic review documenting that benzodiazepines are involved in nearly 30% of opioid overdose deaths. Maps global prevalence of misuse and identifies key risk populations.
2025 narrative review examining how benzodiazepines potentiate respiratory depression through complex drug interactions and hepatic dysfunction, producing increased opioid serum concentrations and exacerbating overdose risk.
2022 large-scale healthcare system study demonstrating that concurrent benzodiazepine and opioid prescriptions significantly increase all-cause mortality, with dose-dependent risk escalation.
2025 ED study finding nearly one-third of confirmed opioid overdose patients had concomitant benzodiazepine exposure. Patients with novel benzodiazepines had significantly higher odds of requiring intubation.
Wang et al. 2016 Aust NZ J Psychiatry. Meta-analysis of 11 studies showing coffee/caffeine consumption associated with decreased depression risk.
2025 comprehensive review covering caffeine's cognitive benefits, physical performance enhancement, cardiovascular risks, addiction potential, and sleep disruption. Documents individual variability in caffeine metabolism due to CYP1A2 genetics.
Gardiner et al. 2023 meta-analysis finding caffeine reduces total sleep time by 45 minutes, increases sleep onset latency, and reduces sleep efficiency. Effects persist up to 8+ hours due to caffeine's variable half-life across individuals.
2024 randomized clinical crossover trial published in SLEEP demonstrating dose-dependent and timing-dependent caffeine effects on polysomnographic sleep measures. Consumption at 3pm reduced sleep more than at 9am.
Havakuk et al. 2021 review of cocaine's cardiac effects including coronary vasospasm, arrhythmias, cardiomyopathy, and aortic dissection. Cocaine causes irreversible structural heart damage and accelerates cardiovascular disease. Published in PMC.
Richards et al. 2016 systematic review of emergency treatment for cocaine-induced tachycardia, hypertension, coronary vasospasm, and acute coronary syndrome. Benzodiazepines remain first-line; beta-blockers are controversial.
2024 systematic review finding crack cocaine exposure causes neuroteratogenic effects, decreased seizure threshold, schizophrenic-like symptoms, and cognitive deficits beyond those of powder cocaine.
2020 Nature Scientific Reports meta-analysis revealing chronic cocaine use is associated with diastolic heart failure rather than the commonly taught dilated cardiomyopathy, challenging standard clinical assumptions.
StatPearls (continuously updated) comprehensive clinical review covering cocaine pharmacology, toxicokinetics, clinical presentation of toxicity, and evidence-based emergency management protocols.
Pereira et al. 2015 study on cocaethylene — the toxic metabolite formed when cocaine and alcohol are co-ingested — which potentiates both cardiac and neurological toxicity beyond either substance alone.
Timmermann et al. 2023 PNAS study using combined EEG-fMRI to map DMT's effects on brain activity in 20 healthy volunteers. First study to capture DMT's neural signature with this methodology.
Alamia et al. 2020 eLife study showing DMT alters direction and magnitude of oscillatory travelling waves in visual cortex during eyes-closed states.
Gallimore & Strassman 2016 paper proposing methodology for extended-state DMT research using anesthesiology infusion techniques. Published in Frontiers in Pharmacology.
Frecska, Bokor, Winkelman 2016 Frontiers in Pharmacology. Comprehensive review of ayahuasca's potential therapeutic applications including depression, addiction, and autoimmune disorders. Discusses sigma-1 receptor mechanisms.
Explores the impact of DMT on mental health, analyzing datasets from prospective studies.
Barker 2018 Frontiers in Neuroscience comprehensive review of endogenous DMT research. Examines DMT biosynthesis in humans, its presence in brain tissue, and potential physiological roles.
Palhano-Fontes et al. 2018 Psychological Medicine first RCT of ayahuasca for depression. Showed significant antidepressant effects within 1-7 days in treatment-resistant patients.
Liu et al. 2017 study on harmine (MAO inhibitor in ayahuasca). Shows harmine has antidepressant effects by restoring astrocyte function, independent of DMT. Published in Prog Neuropsychopharmacol Biol Psychiatry.
Nichols 2017 critical review examining claims about pineal DMT. Concludes endogenous DMT concentrations are far too low to produce psychoactive effects. Important for scientific accuracy. Published in J Psychopharmacology.
Davis, Griffiths et al. 2020 Johns Hopkins survey (N=2,561). Majority reported entity encounters during DMT experiences. 58% met criteria for 'mystical experience'. Published in J Psychopharmacology.
Cameron, Olson et al. 2019 ACS Chemical Neuroscience. First study showing chronic microdosing with DMT produces positive mood and anxiety effects in rodents. Important for microdosing research.
Zeifman et al. 2020 Psychopharmacology. Single-dose ayahuasca produced rapid and sustained reductions in suicidal ideation in treatment-resistant depression patients.
Timmermann et al. 2019 Scientific Reports. EEG study revealing DMT increases oscillatory power at lower frequencies and increases signal diversity, correlating with subjective intensity.
Luan, Rosas et al. 2023 PsyArXiv Preprint. First study using continuous IV infusion to maintain extended DMT state. Documented psychological and physiological effects over 30+ minutes.
Palhano-Fontes et al. 2021 Current Topics in Behavioral Neurosciences. Review of ayahuasca clinical trials for depression, including RCT evidence and neurobiological mechanisms.
Eliasen et al. 2025 Brain Research. Study showing DMT and ibogaine produce distinct membrane effects via 5-HT2A receptor binding in transfected cells.
Aicher et al. 2024 Frontiers in Psychiatry. Controlled trial testing ayahuasca-inspired DMT+harmine formulation in healthy volunteers for safety and acute effects.
dos Santos, Hallak 2025 CNS Spectrums. Comprehensive review of ayahuasca/DMT pharmacology, safety profile, toxicity data, and therapeutic applications.
Paley 2021 Protein Biosynthesis Interference in Disease. Chapter on DMT toxicity, psychoactive effects, and analytical methods for quantifying tryptamines.
Colon-Berezin et al. 2019 CDC MMWR. Epidemiological analysis of fentanyl overdose deaths showing dramatic increase from 2 to 57% of overdose deaths.
Halifax et al. 2024 Harm Reduction Journal. Laboratory evaluation of fentanyl test strip accuracy for harm reduction applications.
O'Donnell et al. 2018 CDC MMWR. Epidemiological report on carfentanil-involved overdose deaths across 10 states, documenting lethal doses and forensic findings.
Walter 2023 JAMA. Clinical overview of fentanyl overdose presentation, treatment with naloxone, and harm reduction strategies.
Zibbell et al. 2019 JAMA Network Open. Analysis correlating carfentanil/fentanyl seizures with overdose mortality, establishing dose-lethality relationships.
Volkow & Blanco 2021 comprehensive review of the four waves of opioid overdose deaths: prescription opioids, heroin, synthetic opioids, and polysubstance use. Covers neurobiology of addiction and promising harm reduction strategies.
2025 systematic review and meta-analysis demonstrating lifesaving effects of community-based naloxone distribution programs. Warrants substantial expansion in nearly every US state.
Irvine et al. 2022 Lancet modelling study estimating naloxone distribution needs across different opioid epidemic phases. Fentanyl overdoses are harder to reverse than heroin overdoses, requiring higher naloxone doses.
Ciccarone 2025 review of the 'fentanyl-plus' era where polysubstance combinations (fentanyl + xylazine, fentanyl + stimulants) define the current overdose crisis. Examines epidemiology, economics, and evolving harm reduction strategies.
Moore et al. 2025 Substance Use & Misuse. Review examining ibogaine's pharmacology and clinical evidence for treating opioid dependence.
Mash et al. 2018 Frontiers in Pharmacology. Clinical observations showing ibogaine detoxification effectively transitions opioid/cocaine users toward abstinence.
Knuijver, Schellekens et al. 2022 Addiction. Open-label observational study (n=14) evaluating ibogaine safety during opioid detoxification. Documented cardiac monitoring protocols and outcomes.
Mosca, Chiappini et al. 2023 Current Neuropharmacology. Systematic review of ibogaine and noribogaine clinical evidence for treating substance use disorders.
Schellekens, Kramers et al. 2022 Addiction. Analysis of ibogaine cardiac toxicity including QT prolongation and arrhythmia risk. Important safety data for ibogaine treatment protocols.
Mestre et al. 2024 Cureus. Case report documenting multiple cardiac arrests during ibogaine treatment, highlighting critical cardiac safety concerns and monitoring requirements.
Gouhie et al. 2023 Brain Disorders. Meta-analysis examining Kanna's anxiolytic effects across multiple studies, finding significant anxiety reduction.
Olatunji et al. 2022 J Ethnopharmacology. Comprehensive review of Kanna's chemistry, pharmacology, and clinical evidence for anxiety and cognitive effects.
Niżnik, Jurowski 2025 Chemico-Biological Interactions. First computational toxicity prediction for kanna's main alkaloid mesembrine, predicting LD50 and key toxicological endpoints.
Manganyi et al. 2021 Molecules. Review of kanna biological activities, safety profile, and pharmaceutical potential including toxicity considerations.
Landmark multi-center RCT (Abdallah et al., 2022) showing dose-related ketamine effects for treatment-resistant PTSD symptoms in veterans and active duty military. Published in Neuropsychopharmacology.
Nature Translational Psychiatry study on personalized ketamine dosing strategies for treatment-resistant depression.
Clinical chart review study examining ketamine-assisted psychotherapy outcomes in trauma-exposed patients.
Liriano, Hatten & Schwartz 2023 review in Therapeutic Advances in Psychopharmacology synthesizing clinical evidence for ketamine in PTSD, including effects on symptom severity and the limits of current trial data.
Journal of Affective Disorders review of ketamine's role in depression and PTSD management.
Bratsos, Saleh 2019 Cureus. Systematic review examining ketamine efficacy in treatment-resistant major depressive disorder.
Daly et al. 2018 JAMA Psychiatry. Phase 2 RCT demonstrating intranasal esketamine efficacy for treatment-resistant depression, leading to FDA approval.
Qin et al. 2023 Eur J Neuroscience. Ketamine increases 'background noise' in thalamo-cortical system, potentially explaining psychosis-like symptoms.
Bonaventura et al. 2021 study showing S-ketamine (not R-ketamine) is responsible for abuse potential. Key for understanding esketamine vs racemic ketamine. Published in Molecular Psychiatry.
Chang, Hashimoto et al. 2019 Pharmacol Biochem Behav. Preclinical comparison showing R-ketamine had greater antidepressant effect with fewer side effects than S-ketamine via intranasal route. Informs enantiomer selection.
Witt et al. 2020 meta-analysis of 15 trials (572 participants) showing single ketamine infusion reduces suicidal thoughts for up to 72 hours. Published in ANZ J Psychiatry.
Grunebaum et al. 2018 American Journal of Psychiatry. Midazolam-controlled RCT showing ketamine rapidly reduced suicidal ideation within 24 hours in major depression. Key evidence for ketamine's anti-suicidal effects.
Singh et al. 2016 Biological Psychiatry RCT establishing esketamine efficacy for treatment-resistant depression. Led to FDA approval of Spravato nasal spray.
Zanos & Gould 2018 Molecular Psychiatry comprehensive review of ketamine's antidepressant mechanisms including NMDA antagonism, AMPA potentiation, and neuroplasticity.
Zarate et al. 2006 landmark NIH study that launched ketamine depression research. First RCT showing single IV ketamine infusion produced rapid antidepressant effects within hours. Published in Arch Gen Psychiatry.
Gould, Zanos, Zarate 2016 Neuropsychopharmacology. Comprehensive review dissecting ketamine's antidepressant mechanisms—NMDA antagonism, AMPA enhancement, mTOR signaling, and metabolite roles. Key mechanistic overview.
Thomas et al. 2018 J Psychopharmacology. Real-world clinical evidence of IV ketamine effectiveness in ultraresistant depression. Identified anhedonia and bipolarity as clinical predictors.
Bloch et al. 2012 Biological Psychiatry. First study of ketamine for treatment-refractory OCD showing rapid but transient anti-obsessional effects.
Wilkinson, Zarate et al. 2018 Am J Psychiatry. Meta-analysis showing single IV ketamine rapidly reduces suicidal ideation within hours, with effects lasting up to one week.
Hochschild, Grunebaum, Mann 2021 Preventive Medicine. Systematic review synthesizing evidence for ketamine's rapid anti-suicidal effects, examining onset, duration, and clinical implications.
Shen, Gao, Lv et al. 2024 Translational Psychiatry. Comprehensive meta-analysis examining ketamine's anti-suicidal effects across multiple trials in depressed patients.
Rogers 2021 Nature Reviews Neuroscience. Structural analysis of ketamine's binding to NMDA receptors revealed through cryo-EM imaging.
Yu & Bhatt 2018 Structure. Structural study of glutamate and glycine co-agonist binding to NMDA receptor, foundational for understanding ketamine's mechanism.
Price et al. 2023 JAMA Network Open. One-year follow-up of RCT showing sustained benefits of IV ketamine combined with digital cognitive training for TRD.
Andrade 2022 J Clinical Psychiatry. Analysis of RCTs comparing ketamine to ECT for severe depression, providing clinical guidance.
KheirAbadi & Golkar 2023 Iranian J Psychiatry and Behavioral Sciences. RCT comparing high vs low dose oral ketamine for TRD control and relapse prevention.
Ouyang & Li 2025 Medicine. Meta-analysis of RCTs evaluating esketamine nasal spray efficacy for treatment-resistant depression.
Coe et al. 2019 Drug Alcohol Dependence. Large survey (n=2,798) showing kratom users primarily use it to manage pain and opioid withdrawal, with low reported adverse effects.
2025 Bangkok Medical Journal. Narrative review examining kratom's pharmacology, clinical potential, and safety considerations.
Papsun et al. 2023 Current Addiction Reports. Forensic analysis of kratom toxicity cases, mitragynine lethal concentrations, and polydrug interactions.
Schmitt et al. 2021 Am J Forensic Med Pathol. Analysis of kratom-associated deaths examining fatal mitragynine blood concentrations and LD50 implications.
Wang, Walker 2018 Academic Forensic Pathology. First documented fatal kratom/mitragynine toxicity case in Canada, establishing baseline lethal dose data.
Farkas et al. 2022 SSRN. Study showing mitragynine's analgesic effects depend on both adrenergic and opioid receptor activation, with sex-dependent variations.
Holze et al. 2022 landmark study directly comparing LSD (100/200µg) and psilocybin (15/30mg) in 28 healthy volunteers. First rigorous head-to-head comparison. Published in Neuropsychopharmacology.
Tagliazucchi, Carhart-Harris et al. 2016 Current Biology. fMRI study showing LSD increases brain functional connectivity, with connectivity changes correlating with subjective ego dissolution experience.
Muthukumaraswamy et al. 2026 Neuroscience Applied. Open-label trial examining LSD microdosing effects on major depressive disorder symptoms.
Holze et al. 2021 Frontiers in Pharmacology. Demonstrates 5-HT2A receptor mediates LSD's prosocial effects on empathy and oxytocin release.
Vizeli et al. 2024 Translational Psychiatry. Analysis of pharmacological and psychological predictors of LSD effects from nine placebo-controlled trials.
Ramaekers et al. 2020 study showing LSD 20µg significantly increased cold water tolerance time and reduced pain ratings. Published in Journal of Psychopharmacology.
Family et al. 2020 Psychopharmacology. First study of LSD (5-20µg) in older adults (55-75 years). Found low doses were well-tolerated with improved mood and cognition. Important for geriatric psychedelic research.
Szigeti et al. 2021 landmark citizen science study with 191 participants. Found microdosing benefits may be explained by placebo effect. Published in eLife.
Wacker/Roth et al. 2017 landmark Cell paper revealing LSD's molecular binding to 5-HT2A/B receptors and why its effects last so long (receptor 'lid' mechanism).
Carhart-Harris et al. 2016 PNAS landmark brain imaging study. First modern fMRI/MEG study of LSD showing increased brain connectivity, visual cortex activation, and ego dissolution neural correlates.
Hutten, Mason et al. 2020 ACS Pharmacol Translat Sci. First study showing microdoses of LSD acutely increase BDNF (brain-derived neurotrophic factor) levels in humans.
Carhart-Harris et al. 2014 Psychopharmacology. Showed LSD increases suggestibility, potentially relevant to therapeutic applications combining psychedelics with psychotherapy.
Gasser, Kirchner & Passie 2014 J Psychopharmacology. Qualitative 12-month follow-up of LSD therapy for end-of-life anxiety. 77.8% reported reduced anxiety, 66.7% improved quality of life. First modern LSD therapy study.
Roseman, Carhart-Harris et al. 2016 Human Brain Mapping. fMRI study showing LSD increases functional connectivity in visual cortex in a retinotopic pattern, explaining closed-eye visual hallucinations.
Polito, Liknaitzky 2024 J Psychopharmacology. Rapid review examining evidence for microdosing effects, finding limited placebo-controlled evidence but consistent self-report improvements.
Howard, Stork 2024 Encyclopedia of Toxicology. Comprehensive toxicology reference entry covering LSD pharmacology, toxicity profile, clinical effects, and treatment guidelines.
Suleria et al. 2025 Cureus. Review examining LSD's cardiovascular effects including heart rate, blood pressure changes, and potential cardiac risks.
Kehler & Lindskov 2025 J Psychopharmacology. Analysis of why some 5-HT2A agonists like lisuride produce therapeutic effects without hallucinogenic properties.
Müller et al. 2019 Swiss Medical Weekly. Neuroimaging review summarizing LSD's acute effects on resting-state brain function and network connectivity.
Ghaw et al. 2024 Brain Communications. fMRI study showing dose-dependent LSD effects on cortical, thalamic, and cerebellar BOLD activity with receptor correlates.
Becker et al. 2022 Neuroscience Applied. Neuroimaging study demonstrating 5-HT2A antagonist ketanserin blocks LSD's subjective and brain activity changes.
Landmark Phase 3 RCT (Mitchell et al., 2021) demonstrating MDMA-assisted therapy for severe PTSD produced significant symptom reductions with favorable safety profile across multiple sites. Published in Nature Medicine.
Müller, Liechti et al. 2021 Neuropsychopharmacology. fMRI study showing MDMA alters brain network connectivity differently than classic psychedelics, highlighting distinct mechanisms of action.
Mithoefer et al. 2018 J Psychopharmacol. Randomized pilot study (n=28) comparing MDMA doses (40mg, 100mg, 125mg) for chronic PTSD. Active doses showed greater symptom reduction; 76% no longer met PTSD criteria at 12-month follow-up.
Mithoefer et al. 2019 Psychopharmacology. Pooled analysis of six Phase 2 trials (n=103) showing MDMA-assisted therapy produced significant PTSD symptom reductions compared to placebo. Key data informing Phase 3 trial design.
Shannon, Geller 2024 Frontiers in Human Neuroscience. Review discussing transformative potential of MDMA-assisted therapy for PTSD and related conditions.
Cristea et al. 2024 JAMA Psychiatry. Critical analysis of psychotherapy components in MDMA-assisted therapy and their contribution to treatment outcomes.
Doss et al. 2018 Neuropsychopharmacology study showing MDMA impairs emotional memory encoding/retrieval. Relevant for understanding PTSD therapy mechanisms - may help reconsolidation of traumatic memories.
Danforth et al. 2018 Psychopharmacology pilot RCT showing MDMA-assisted therapy reduced social anxiety in autistic adults. First study of MDMA therapy in autism spectrum population.
Sessa et al. 2021 J Psychopharmacology. First study of MDMA-assisted therapy for alcohol dependence. Showed safety, tolerability, and promising efficacy signals in reducing drinking.
Szigeti, Winstock et al. 2018 J Psychopharmacology. Global Drug Survey analysis suggesting serotonergic neurotoxicity claims from MDMA use may be overstated for typical recreational users.
Kuypers, Liechti et al. 2017 J Psychopharmacology. Pooled analysis showing single MDMA doses enhance emotional empathy while cognitive empathy remains intact. Supports therapeutic mechanism for PTSD.
Wolfson et al. 2020 Scientific Reports. MAPS pilot RCT showing MDMA-assisted therapy reduced anxiety in patients with life-threatening illnesses. First study extending MDMA therapy beyond PTSD.
Costa, Gołembiowska 2022 Experimental Neurology. Comprehensive review of MDMA neurotoxicity mechanisms including serotonergic damage, oxidative stress, hyperthermia, and therapeutic implications.
Trychta, Harvey 2022 Int J Mol Sci. Research showing caffeine combined with MDMA worsens hyperthermia-induced cellular stress, important safety data for polydrug use scenarios.
Islas & Scior 2022 Molecules. Computational study revealing MDMA's allosteric binding mechanism at human serotonin transporter using induced fit docking and Monte Carlo simulations.
Vizeli et al. 2019 ACS Chem Neuroscience. Pharmacogenetic study showing how genetic variations in serotonin transporter and receptors affect individual MDMA response.
Mullard 2023 Nature Reviews Drug Discovery. News coverage of MDMA-assisted therapy Phase III success for PTSD treatment.
Maples-Keller et al. 2025 Contemporary Clinical Trials Communications. Protocol paper for clinical trial combining massed exposure therapy with MDMA for PTSD.
Dinis-Oliveira et al. 2019 Current Molecular Pharmacology. Comprehensive review of mescaline/peyote pharmacokinetics, metabolism, and clinical implications.
2023 Molecules. Review examining mescaline pharmacology, traditional ceremonial use in Native American Church, and modern therapeutic potential.
2010 Clinical Toxicology. Retrospective analysis of mescaline/peyote exposure reports documenting clinical presentation and outcomes.
Jayanthi et al. 2021 review of METH-induced neurotoxicity mechanisms including oxidative stress, mitochondrial dysfunction, dopamine/serotonin terminal degeneration, and neuroinflammation via microglial activation. Published in PMC.
Moszczynska & Callan 2017 comprehensive review covering METH's effects on striatum, prefrontal cortex, and hippocampus. MRI/PET imaging shows structural brain changes in chronic users. No FDA-approved therapy exists for METH neurotoxicity.
2024 review of METH neurotoxic effects including attention deficit, memory loss, and cognitive decline mediated through oxidative stress, excitotoxicity, DNA damage, and apoptosis pathways.
Meftahi et al. 2022 review of METH-induced Parkinson's-like symptoms, psychosis, and cognitive disorders. Covers experimental treatment strategies targeting oxidative stress, neuroinflammation, and mitochondrial impairment.
Kesby et al. 2016 preclinical study demonstrating chronic METH exposure causes persistent structural brain changes including reduced prefrontal cortex volume and impaired cognitive flexibility, even after extended abstinence.
Muthukumaraswamy et al. 2021 Expert Review of Clinical Pharmacology. Analysis of blinding challenges in psychedelic trials and implications for interpreting treatment effects.
Huneke et al. 2025 JAMA Psychiatry. Analysis of expectancy effects and blinding failures across psychiatric treatment trials including psychedelics.
Landmark Griffiths et al. 2006 study showing psilocybin produces mystical experiences with lasting personal and spiritual significance. One of the foundational modern psilocybin studies. Published in Psychopharmacology.
Vargas et al. 2023 Science paper discovering that psychedelics promote neuroplasticity via intracellular (not cell-surface) 5-HT2A receptors, explaining why serotonin doesn't trigger comparable effects.
Irizarry et al. 2022 meta-analysis of 9 studies showing psilocybin improves symptoms in anxiety, depression, OCD, PTSD, and substance abuse. Published in Cureus.
Roseman et al. 2018 Neuropharmacology. fMRI study showing psilocybin increased (not decreased) amygdala responses to emotional faces in treatment-resistant depression, suggesting enhanced emotional processing rather than blunting.
Erkizia-Santamaría et al. 2022 study examining psilocybin's interaction with 5-HT2A, 5-HT2C, and 5-HT1A receptors and effects on thermoregulation. Published in Biomedicine & Pharmacotherapy.
Madsen et al. 2019 Neuropsychopharmacology. PET imaging study (n=15) showing psilocybin's subjective effects correlate with 5-HT2A receptor occupancy in the brain and plasma psilocin levels. Key pharmacokinetic data.
Becker, Liechti et al. 2022 Clin Pharmacol Ther. Randomized crossover study in 23 healthy volunteers after 14 days of escitalopram or placebo pretreatment. Escitalopram did not reduce overall 3D-OAV scores or meaningfully change positive mood effects; selected negative effects and anxiety decreased. This short study does not establish effects or safety of long-term SSRI co-treatment in patients with psychiatric conditions.
Gotvaldová et al. 2022 study quantifying psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin in 226 mushroom samples. Key finding: tryptamine concentrations are extremely variable. Published in IJMS.
Kwan et al. 2022 Nature Neuroscience review on how psilocybin, LSD, and mescaline produce effects via 5-HT2A receptor signaling, neuroplasticity, and brain network alterations.
Sweeney/Griffiths et al. 2022 Johns Hopkins study of 3,192 participants comparing psychedelics (LSD, psilocybin, DMT, ayahuasca) with NDEs. ~90% reported decreased fear of death. Published in PLOS ONE.
Griffiths et al. 2016 landmark Johns Hopkins RCT showing psilocybin produced sustained decreases in depression/anxiety in cancer patients. Published in Journal of Psychopharmacology.
Landmark Johns Hopkins RCT (Davis et al., 2021) showing psilocybin-assisted therapy produced large, rapid, and sustained antidepressant effects in patients with major depressive disorder. Published in JAMA Psychiatry.
Explores physiological and psychological moderators during psilocybin administration in healthy volunteers.
Systematic review of psychoplastogens, including psilocybin, and their effects on brain-derived neurotrophic factor levels.
Investigates the potential of psilocybin as an anti-nociceptive agent for chronic pain treatment.
Comprehensive review of neuroplastic effects of classic psychedelics like psilocybin.
Study analyzing the synergistic effects of psilocybin combined with NMDA receptor modulators.
Carhart-Harris et al. 2016 landmark Lancet Psychiatry study - first modern clinical trial of psilocybin for depression. All 12 patients showed reduced depression symptoms at 1 week, with 67% in remission at 3 months.
Ly, Olson et al. 2018 Cell Reports landmark paper showing DMT, LSD, and psilocin promote dendritic arbor complexity, spinogenesis, and synaptogenesis. Foundational evidence for psychedelic neuroplasticity.
Raison et al. 2023 JAMA Phase 2 RCT. Single 25mg synthetic psilocybin dose produced significantly reduced depression ratings vs placebo through 43 days in 104 participants.
Johnson, Griffiths et al. 2018 Neuropharmacology analysis. Systematic evaluation concluding psilocybin has low abuse potential, supporting rescheduling. Key policy paper.
Malcolm & Thomas 2022 Psychopharmacology review examining serotonin syndrome risk with psychedelics. Key harm reduction paper on drug interactions with MAOIs, SSRIs, and other serotonergics.
Johansen & Krebs 2015 J Psychopharmacology landmark population study (N=135,000+). Found no associations between lifetime psychedelic use and mental health problems. Key safety evidence.
Johnson, Griffiths et al. 2014 Johns Hopkins pilot study. 15 participants achieved 80% smoking abstinence at 6 months - far exceeding typical cessation rates. Published in J Psychopharmacology.
Agin-Liebes et al. 2020 NYU long-term follow-up (4.5 years) of cancer patients. ~60-80% showed clinically significant reductions in anxiety/depression. Published in J Psychopharmacology.
Carhart-Harris et al. 2017 Scientific Reports. fMRI study showing psilocybin decreased amygdala blood flow and altered default mode network connectivity in treatment-resistant depression.
Ross et al. 2016 NYU RCT (companion to Griffiths study). Single psilocybin dose with psychotherapy reduced cancer-related anxiety/depression with 60-80% maintaining benefits at 6.5 months. Published in J Psychopharmacology.
Doss et al. 2021 Johns Hopkins Translational Psychiatry study. Psilocybin increased cognitive flexibility and reduced neural rigidity in depression, suggesting mechanism for therapeutic effects.
Spriggs, Carhart-Harris et al. 2021 Frontiers in Psychiatry. First study protocol for psilocybin treatment of anorexia nervosa, addressing rigid thought patterns and self-perception in eating disorders.
Hendricks et al. 2017 J Psychopharmacology population study. Classic psychedelic use associated with reduced odds of criminal behavior including theft, assault, and property crime.
Barrett, Griffiths et al. 2020 Scientific Reports. Single psilocybin dose produced sustained improvements in positive affect and reduced anxiety lasting at least one month.
Rucker et al. 2022 J Psychopharmacology Phase 1 trial in healthy volunteers. Established safety profile and showed psilocybin effects on cognition and emotion without lasting impairment.
Carbonaro, Griffiths et al. 2020 Psychopharmacology. Compared psilocybin to active placebo (DXM). Psilocybin produced unique mystical-type experiences not seen with DXM.
Kaertner, Carhart-Harris et al. 2021 Scientific Reports. Showed microdosing benefits may be significantly influenced by expectation/placebo effects. Important for interpreting microdosing research.
Kuypers et al. 2019 J Psychopharmacol systematic review of microdosing research. Found mostly anecdotal evidence; called for rigorous RCTs examining potential risks of repeated low doses.
Petranker et al. 2020 J Psychopharmacol. Global Drug Survey (n=6,753) showing microdosers report benefits (mood, creativity) and challenges (illegal status, dosing uncertainty). Intention predicts outcomes.
Mason, Kuypers, Ramaekers et al. 2020 Neuropsychopharmacology. MRS neuroimaging showing psilocybin reduces glutamate in hippocampus and prefrontal cortex, correlating with ego dissolution experience.
Gukasyan, Davis et al. 2022 J Psychopharmacol. 12-month follow-up showing sustained antidepressant effects: 75% showing significant improvement, 58% achieving remission at 12 months.
Carhart-Harris et al. 2018 Psychopharmacology. Six-month follow-up to 2016 Lancet study showing sustained depression remission in treatment-resistant patients.
Carhart-Harris 2019 Current Opinion in Psychiatry review examining mechanisms of action underlying psychedelic effects: 5-HT2A activation, entropic brain theory, and therapeutic implications.
Nardou, Dölen et al. 2023 Nature. Landmark study showing MDMA, LSD, psilocybin, ibogaine, and ketamine reopen critical period for social reward learning in mice. Duration of effect correlated with therapeutic potential.
Singleton, Carhart-Harris et al. 2022 Nature Communications. Shows LSD and psilocybin reduce brain control energy needed for state transitions using network control theory and 5-HT2A mapping.
Inserra, Gobbi et al. 2021 Pharmacological Reviews comprehensive review. Examines mechanisms underlying psychedelic psychiatric applications including neuroplasticity, immunomodulation, and neurotransmitter effects.
Griffiths, Johnson et al. 2018 J Psychopharmacology. Psilocybin combined with meditation/spiritual practices produced lasting improvements in psychological functioning and prosocial behaviors at 6-month follow-up.
McCulloch et al. 2022 J Psychopharmacology. Single psilocybin dose produced lasting changes in brain resting-state connectivity associated with positive clinical and wellbeing outcomes.
Stenbaek et al. 2020 J Psychopharmacology. PET study showing individual differences in 5-HT2A receptor binding predict mystical-type experience intensity from psilocybin.
Kaelen et al. 2018 Psychopharmacology. Shows music plays a central therapeutic role during psilocybin/LSD sessions, influencing emotional breakthroughs and treatment outcomes.
Peill, Carhart-Harris et al. 2022 J Psychopharmacology. Validated a new psychometric tool measuring psychological insight from psychedelic experiences. Insight predicted therapeutic outcomes.
Lyons & Carhart-Harris 2018 J Psychopharmacology. Found psilocybin therapy significantly increased nature connectedness and decreased authoritarian political views in depression patients at 7-12 month follow-up.
Rucker & Young 2021 Frontiers in Psychiatry. Reviews psilocybin's therapeutic potential based on early-phase clinical trials and discusses ethical concerns about commercial psychedelic retreat centers.
Millière, Carhart-Harris et al. 2018 Frontiers in Psychology. Reviews how psychedelics and meditation alter self-consciousness through shared neurobiological mechanisms affecting sense of self and ego dissolution.
Carhart-Harris & Nutt 2017 J Psychopharmacology. Landmark theory paper proposing psychedelics (5-HT2A agonists) enhance plasticity and active coping, contrasting with SSRIs (5-HT1A). Key framework for understanding psychedelic mechanisms.
Rucker, Iliff & Nutt 2018 Neuropharmacology. Comprehensive review of psychedelics in psychiatry covering history, current research on psilocybin/LSD/mescaline, and future therapeutic potential.
Daws, Carhart-Harris et al. 2022 Nature Medicine. fMRI study showing psilocybin therapy increases brain network integration in depression, with changes correlating with symptom improvement.
Goodwin et al. 2022 NEJM. Large Phase 2b RCT (n=233) showing 25mg psilocybin produced significant depression reduction vs 1mg control at 3 weeks. First NEJM psilocybin trial.
Jacobs 2020 J Psychedelic Studies. Review examining psilocybin's potential for OCD treatment based on serotonin 2A receptor agonism and preliminary clinical evidence.
Leighton et al. 2025 Cephalalgia Reports. Case series documenting successful treatment of cluster headache with serotonergic psychedelics and ketamine.
Sharifan 2025 Cochrane Clinical Answers. Cochrane systematic review examining evidence for psilocybin and LSD in treating psychological distress in terminal illness.
Bogenschutz, Ross et al. 2022 JAMA Psychiatry. Landmark RCT (n=93) showing psilocybin-assisted therapy significantly reduced heavy drinking days compared to placebo. First major trial for psilocybin in alcohol use disorder.
McCulloch et al. 2022 Neuroscience Applied. Neuroimaging study showing psilocybin acutely increases brain entropy, providing mechanistic insights into psychedelic state.
Straumann, Holze et al. 2024 Neuroscience Applied. Comprehensive safety/toxicity assessment of acute psilocybin showing favorable safety profile in healthy volunteers.
Wiegand 2024 Encyclopedia of Toxicology. Comprehensive toxicology reference entry covering psilocybin mushroom identification, toxicity profile, clinical presentation, and treatment guidelines.
Rahbarnia et al. 2025 Psychopharmacology. Study examining how psilocybin's 5-HT2A receptor binding affects visual attention using selective agonists and antagonists.
Drewko et al. 2025 Molecular Psychiatry. Review exploring how 5-HT2A receptor activation drives neuroplasticity and antidepressant effects of psychedelics.
Pottie & Stove 2022 J Neurochemistry. Methodological paper on in vitro assays for characterizing psychedelic binding and functional activity at 5-HT2A receptors.
Gumpper & Nichols 2024 Br J Pharmacology. Comprehensive review of psychedelic drug chemistry and structural biology of serotonin receptor binding.
Madsen et al. 2023 Neuroscience Applied. PET imaging study comparing 5-HT2A receptor occupancy of psychedelic vs non-psychedelic compounds in vivo.
Łukasiewicz et al. 2018 5-HT2A Receptors in the CNS. Chapter on 5-HT2A receptor heterodimerization and implications for psychedelic signaling.
Smigielski et al. 2019 NeuroImage. fMRI study showing psilocybin combined with mindfulness meditation produces lasting changes in DMN connectivity and self-consciousness.
Zeifman et al. 2025 Scientific Reports. Empirical test of REBUS model showing psilocybin enables belief revision through relaxed high-level priors in brain hierarchy.
O'Leary 2024 Nature Medicine. News feature summarizing neuroimaging findings on psilocybin's effects on brain connectivity and neural networks.
Lewis-Healey et al. 2022 Psychology & Neuroscience. Framework proposing psilocybin's therapeutic effects work through relaxing pathological symptom networks in the brain.
Calvey & Howells 2018 Progress in Brain Research. Foundational chapter introducing neuroimaging methods for studying psychedelic effects on brain function.
Weiss et al. 2025 Brain Sciences. Comprehensive review of neuroimaging evidence for psychedelic-induced neural plasticity and clinical applications.
Ertl & Wall 2024 The Biochemist. Overview of neuroimaging techniques used to study psychedelic effects on brain activity and connectivity.
Jang et al. 2024 Brain Sciences. Neuroimaging analysis using graph theory to classify and compare brain states under psychedelics vs other altered states.
Calarco 2024 Nature Reviews Psychology. Review of neuroimaging studies examining claustrum's role in consciousness, relevant to psychedelic mechanisms.
Levin 2025 J Psychopharmacology. Novel neuroimaging-based hypothesis that psychedelics promote interhemispheric connectivity and reduce lateralization.
Schindler et al. 2025 Headache. Exploratory RCT comparing single and repeat psilocybin doses versus active placebo for migraine prevention.
Yu et al. 2021 Psychiatry Investigation. Systematic review and meta-analysis of psilocybin trials for anxiety in terminal illness patients.
Yaniv et al. 2023 Int J Gynecological Cancer. Review of psilocybin-assisted psychotherapy trials for anxiety and depression in cancer patients.
Dino 2025 Cureus. Comprehensive overview of psilocybin clinical trials for depression, TRD, and end-of-life distress.
Butelman, Kreek 2015 Frontiers in Pharmacology. Comprehensive review of salvinorin A pharmacology as a selective kappa-opioid agonist and potential therapeutic applications.
Brito-da-Costa et al. 2021 Pharmaceuticals. Review of salvinorin A pharmacokinetics, metabolism, and clinical implications for forensic assessment.
Calado et al. 2025 Int J Mol Sci. Comprehensive toxicology review covering salvinorin A safety profile, LD50 data, adverse effects, and therapeutic potential.
Puls & Wolber 2023 Molecules. Computational study elucidating salvinorin A's unique binding mode at kappa opioid receptor, explaining its selective agonism.
Roach & Shenvi 2018 Bioorg Med Chem Lett. Review of salvinorin A analogs and structure-activity relationships for kappa opioid receptor binding.
Krengel et al. 2019, Chemistry & Biodiversity. Characterizes the iboga-type indole alkaloids (coronaridine, ibogamine, voacangine, ibogaine) found across Tabernaemontana - the genus Sananga is made from.
Estevez et al. 2007, Journal of Ethnopharmacology. Tabernaemontana sananho (a Sananga source species) showed good in-vitro activity against Leishmania - an anti-parasite finding, not an eye study.
Marques et al. 2018, International Journal of Molecular Sciences. Tabernaemontana catharinensis extract reduced paw edema and pro-inflammatory cytokines in animal models; illustrates genus bioactivity, not ocular use.
Prajna 1999, Indian Journal of Ophthalmology. ~48% of corneal-ulcer patients had used traditional eye remedies - the safety context for putting non-sterile substances like Sananga on the eye.
Arunga et al. 2019, Wellcome Open Research. Traditional-eye-medicine users presented later, with larger corneal ulcers and worse visual outcomes - directly relevant to Sananga's ocular risk.
2015, example of preclinical bioactivity of coronaridine (a principal Sananga alkaloid). Lab activity of an isolated alkaloid - not evidence the eye drop is therapeutic.
Chaves et al. 2020 Pain Medicine. RCT showing THC-rich cannabis oil significantly reduced pain and improved quality of life in fibromyalgia patients.
Sharpe et al. 2020 J Translational Medicine. Critical appraisal of cannabis anxiolytic vs anxiogenic effects with clinical implications for anxiety disorders.
Lichenstein 2022 Current Addiction Reports. Review of dose-dependent anxiolytic and anxiogenic effects of THC and CBD from recent literature.
2019 Pediatric Emergency Care. Clinical review of acute cannabis toxicity presentations in pediatric and adult patients, treatment guidelines, and emerging trends.
Baltz, Le 2020 Clinical Practice and Cases in Emergency Medicine. Case report distinguishing cannabis toxicity from serotonin syndrome, important for differential diagnosis.
Ibsen et al. 2019 Frontiers in Pharmacology. Study of CB1 and CB2 receptor signaling via arrestin translocation across species and agonist types.
2021 Methods in Cell Biology. Review of protein-protein interactions at cannabinoid receptors and implications for signal transduction.